You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股表現》科濟藥業(02171.HK)暗盤高開19%報39元
阿思達克 06-17 16:15
根據輝立交易平台顯示,明天掛牌的科濟藥業(02171.HK)暗盤高開19%報39元欠承接,掉頭低見32元,現造32.3元,較上市價32.8元,低1.5%,成交47萬股。

科濟是一家在中國及美國擁有業務而未有盈利生物製藥公司,其專注於治療血液惡性腫瘤和實體瘤的創新CAR-T細胞療法,並已內部開發新技術及擁有全球權益的產品管線,以解決CAR-T細胞療法重大挑戰。是次來港上市共發售近9,475萬股,並已引入包括禮來亞洲基金、新華人壽、CloudAlpha、睿遠、WT基金、廣發証券、Dymon Asia、常春藤及南方基金等九名基石投資者,合共認購4,732.2萬股(設有6個月禁售期);其中10%公開發售獲近434倍超購,已啟動回撥機制佔比增至50%,認購一手中籤率僅5%,股份以招股範圍(29.6-32.8元)上限定價,料集資淨額約29.4億元,主要用於為進一步開發公司核心候選產品BCMA CAR-T(CT053)和正在進行兼已籌劃其他管線候選產品研發活動提供資金、開發全面製造及商業化能力、繼續升級公司的CAR-T技術及為早期研發活動提供資金等。上市聯席保薦人為高盛及瑞銀。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account